Table 1.
Patient characteristics, response to sorafenib, and outcome
| Pts. nb. | Age at diagn. (years) | Type of can. | Sex | Stage at diagn. | Nb. sorafenib line therapy | CHT parallel to sorafenib | Age at sorafenib | Length of therapy (days) | Best response | Time to the best response | Toxicity (grades 2–3) | Reason for stopping therapy | Status at last follow up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2.6 | ES | F | Met | 1 | IFO, TC | 4.1 | 40 | PD | – | – | PD | AWD |
| 2 | 15.7 | CHS | M | Met | 4 | – | 20.8 | 56 | PR | 30 | – | PD | DOD |
| 3 | 19.9 | OS | F | Met | 1 | VP, IFO | 20.5 | 147 | PR | 26 | Skin | Toxicity | AWD |
| 4 | 14.5 | OS | F | Loc | 2 | – | 21.3 | 299 | PR | 66 | – | PD | DOD |
| 5 | 11.0 | OS | F | Loc | 6 | ADM, GMZ | 19.6 | 214 | PR | 80 | – | PD | DOD |
| 6 | 18.4 | OS | M | Met | 5 | – | 27.9 | 71 | PR | 35 | – | PD | DOD |
| 7 | 6.7 | OS | M | Met | 3 | DTIC,VP, CTX | 7.6 | 114 | PR | 41 | – | PD | DOD |
| 8 | 3.5 | CHS | M | Met | 2 | VP, CBDCA | 4.1 | 60 | PD | – | – | PD | DOD |
| 9 | 13.6 | OS | M | Met | 2 | GMZ, DCT | 16.2 | 15 | SD | 15 | Skin | Toxicity | NED |
| 10 | 18.5 | ES | M | Met | 2 | – | 21.9 | 50 | PR | 32 | – | PD | DOD |
| 11 | 13.3 | OS | M | Met | 1 | – | 16.3 | 13 | SD | 13 | Skin | Toxicity | NED |
| 12 | 12.8 | OS | M | Met | 1 | VP, IFO | 13.0 | 118 | PR | 69 | – | Surgery | DOD |
Nb number, ES Ewing sarcoma, OS osteosarcoma, CHS chondrosarcoma, Met metastases, Loc localize, TC topotecan, cyclophosphamide, IFO ifosfamide, GMZ gemcitabine, DCT docetaxel, CTX cyclophosphamide, VP etoposide, ADM adriamycin, DTIC dacarbazine, CBDCA carboplatin, PR partial response, SD stable disease, PD progression disease, DOD death of disease, NED no evidence of disease, AWD alive with disease